Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Introduction

Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven consensus recommendations regarding COVID-19 vaccinations in HS patients.

Methods

A modified Delphi consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until consensus (≥70% agreement) was achieved.

Results

Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round.

Discussion/Conclusion

For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.

Related collections

Most cited references 13

Record: found
Abstract: found
Article: found

Is Open Access

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Malik Sallam (2021)

Utility of vaccine campaigns to control coronavirus 2019 disease (COVID-19) is not merely dependent on vaccine efficacy and safety. Vaccine acceptance among the general public and healthcare workers appears to have a decisive role in the successful control of the pandemic. The aim of this review was to provide an up-to-date assessment of COVID-19 vaccination acceptance rates worldwide. A systematic search of the peer-reviewed English survey literature indexed in PubMed was done on 25 December 2020. Results from 31 peer-reviewed published studies met the inclusion criteria and formed the basis for the final COVID-19 vaccine acceptance estimates. Survey studies on COVID-19 vaccine acceptance rates were found from 33 different countries. Among adults representing the general public, the highest COVID-19 vaccine acceptance rates were found in Ecuador (97.0%), Malaysia (94.3%), Indonesia (93.3%) and China (91.3%). However, the lowest COVID-19 vaccine acceptance rates were found in Kuwait (23.6%), Jordan (28.4%), Italy (53.7), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%). Only eight surveys among healthcare workers (doctors and nurses) were found, with vaccine acceptance rates ranging from 27.7% in the Democratic Republic of the Congo to 78.1% in Israel. In the majority of survey studies among the general public stratified per country (29/47, 62%), the acceptance of COVID-19 vaccination showed a level of ≥70%. Low rates of COVID-19 vaccine acceptance were reported in the Middle East, Russia, Africa and several European countries. This could represent a major problem in the global efforts to control the current COVID-19 pandemic. More studies are recommended to address the scope of COVID-19 vaccine hesitancy. Such studies are particularly needed in the Middle East and North Africa, Sub-Saharan Africa, Eastern Europe, Central Asia, Middle and South America. Addressing the scope of COVID-19 vaccine hesitancy in various countries is recommended as an initial step for building trust in COVID-19 vaccination efforts.

0 comments Cited 906 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis

Alexandra B. Kimball, Murali Sundaram, Geneviève Gauthier … (2018)

Introduction Prior studies have reported that hidradenitis suppurativa (HS) is accompanied by a myriad of physical and mental conditions. However, given the small sample sizes and the limited number of pre-selected comorbidities, these studies do not provide a complete picture of the comorbidity burden of HS in the USA. Moreover, the relationship between HS severity and comorbidity burden has yet to be characterized. Using a large US claims database, we estimated the comorbidity burden associated with HS, stratified by disease severity. Methods A retrospective matched cohort design was used. Patients with HS were classified into two severity cohorts (milder and more severe) using an empirical algorithm based on treatments received. The comorbidity burden was compared between each HS cohort and their matched HS-free cohort, and between patients with milder vs. those with more severe forms of HS. Results Several physical and mental comorbidities were found to be more prevalent in both cohorts of patients with milder and more severe forms of HS than in their matched HS-free cohorts. The comorbidity burden also increased greatly as the disease progressed to more severe forms. Conclusions The results of this study highlight the complexity of the comorbidity burden of HS patients and the need for a multidisciplinary approach to optimize the management of HS and its numerous associated comorbidities. Funding AbbVie, Inc. Electronic supplementary material The online version of this article (10.1007/s13555-018-0264-z) contains supplementary material, which is available to authorized users.

0 comments Cited 33 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: found

Global Hidradenitis Suppurativa COVID‐19 Registry: A Registry to Inform Data‐Driven Management Practices

H.B. Naik, R Alhusayen, J. Frew … (2020)

Abstract The management of hidradenitis suppurativa (HS), a chronic inflammatory skin disease, deserves special consideration in the context of the Coronavirus 2019 (COVID‐19) pandemic. A new Global Hidradenitis Suppurativa COVID‐19 Registry has been developed to capture data on risks, clinical course, and outcomes of COVID‐19 in HS patients. Caused by the virus SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus‐2), COVID‐19 is an easily transmissible disease which, in its most severe form, is characterized by respiratory failure and multiple organ dysfunction triggered by a cytokine storm response that predominates in older adults and those with significant comorbidities.

0 comments Cited 8 times – based on 0 reviews      Review now

All references

Author and article information

Journal

Journal ID (nlm-ta): Skin Appendage Disord

Journal ID (iso-abbrev): Skin Appendage Disord

Journal ID (publisher-id): SAD

Title: Skin Appendage Disorders

Publisher: S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )

ISSN (Print): 2296-9195

ISSN (Electronic): 2296-9160

Publication date (Print): July 2022

Publication date (Electronic): 10 January 2022

Publication date PMC-release: 10 January 2022

Volume: 8

Issue: 4

Pages: 287-290

Affiliations

[1] ^aDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

[2] ^bJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA

[3] ^cDavid Geffen School of Medicine, University of California, Los Angeles, California, USA

[4] ^dDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota, USA

[5] ^eDepartment of Dermatology Hershey, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

[6] ^fDepartment of Dermatology, University of California, San Francisco, San Francisco, California, USA

[7] ^gDepartment of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia

[8] ^hDepartment of Dermatology Chapel Hill, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

[9] ⁱDivision of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA

Author notes

*Vivian Y. Shi, vivian.shi.publications@ 123456gmail.com

Article

Publisher ID: sad-0008-0287

DOI: 10.1159/000521268

PMC ID: 9274824

PubMed ID: 35979524

SO-VID: 31fa27f3-219f-49c8-8327-6e75b7cfb079

License:

This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 14 October 2021

Date accepted : 24 November 2021

Date: 2022

Page count

Figures: 1, Tables: 1, References: 8, Pages: 4

Comments

Comment on this article

Cited by 1

Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation
Authors: Emily K. Kozera, Martina Porter, So Yeon Paek …

See all cited by

Most referenced authors 65

See all reference authors

- Version 1

Call for Papers: Skin Health in Aging Populations

Submit here by August 31, 2025